Association of SARS-CoV-2 IgG Antibody Levels with Clinical/Laboratory Characteristics in COVID-19 Patients: Data from a Turkish Study

Basit Öğe Kaydı
dc.authoridKARAALI, Ridvan/0000-0003-2440-7529
dc.authoridAygun, Gokhan/0000-0001-6915-9843
dc.authoridOZDEMIR, YUSUF EMRE/0000-0002-7428-5091
dc.authoridBEYTUR, AYSE NUR/0000-0002-8001-5880
dc.authoridTuyji Tok, YESIM/0000-0003-4970-9216
dc.contributor.authorKaraali, Ridvan
dc.contributor.authorDinc, Harika O.
dc.contributor.authorOzdemir, Yusuf E.
dc.contributor.authorDalar, Zeynep G.
dc.contributor.authorKurt, Ahmet F.
dc.contributor.authorAktas, Ayse N.
dc.contributor.authorSirekbasan, Serhat
dc.date.accessioned2025-01-27T20:20:50Z
dc.date.available2025-01-27T20:20:50Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: COVID-19 causes clinical manifestations ranging from asymptomatic infection to multi-organ failure. It is reported that those with severe disease have higher anti-SARS-CoV-2 antibody titers compared to asymptomatic or mild cases. We evaluated the correlation of antibody responses with laboratory and clinical indicators in COVID-19 patients. Methods: Seventy-nine male and 66 female patients (mean age: 39) with at least one positive SARS-CoV-2 RTPCR test and SARS-CoV-2 IgG antibody result after acute infection were included. Results: Seventy-six (52%), 45 (31%), and 24 (17%) patients had mild, moderate, and severe clinical findings, respectively. Patients with high body mass index and advanced age had significantly more severe disease (p < 0.001). A significant correlation was found between the increase in lymphopenia, C-reactive protein, ferritin, D-dimer, and lactate dehydrogenase and the severity of clinical findings (p = 0.0001). SARS-CoV-2 IgG antibody test was positive in 128 (88.3%) patients. A significant correlation was found between disease severity and antibody levels in the comparison of all groups (p < 0.001). Conclusions: Long-term monitoring of immune responses will be required to determine the appropriate time for the administration of new vaccines.
dc.identifier.doi10.7754/Clin.Lab.2021.211230
dc.identifier.endpage1893
dc.identifier.issn1433-6510
dc.identifier.issue9
dc.identifier.pmid36125145
dc.identifier.scopus2-s2.0-85138137833
dc.identifier.scopusqualityQ3
dc.identifier.startpage1887
dc.identifier.urihttps://doi.org/10.7754/Clin.Lab.2021.211230
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21828
dc.identifier.volume68
dc.identifier.wosWOS:000866477600001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherClin Lab Publ
dc.relation.ispartofClinical Laboratory
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectSARS-CoV-2
dc.subjectRT-PCR
dc.subjectserology
dc.subjectpublic health
dc.titleAssociation of SARS-CoV-2 IgG Antibody Levels with Clinical/Laboratory Characteristics in COVID-19 Patients: Data from a Turkish Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu